ImmVirX and Innovent Expand Collaboration to Investigate IVX037 with TYVYT® in Liver Cancer
Melbourne, Australia 28 April 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to announce it has expanded its clinical trial collaboration and supply agreement with Innovent Biologics, Inc. […]
